Publications

5674 Results

Phase I and randomized phase II trial of gemcitabine, erlotinib, and IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first line treatment in patients with metastatic pancreatic cancer (SWOG-0727)

Authors
PA Philip;B Goldman;R Ramanathan;HJ Lenz;A Lowy;RP Whitehead;S Iqbal;R Gaur;J Benedetti;CD Blanke
Journal / Conference
Journal of Clinical Oncology 30(suppl 4; abstr 198); ASCO 2012 GI Cancers Symposium, poster;
Year
2012
Research Committee(s)
Gastrointestinal
Study Number(s)
S0727

Use of EGF A61G polymorphism predicts overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205)

Authors
J Labonte;B Goldman;Wu Zhang;M Labonte;C Blanke;P Philip;R Wong;E O'Reilly;J Benedetti;HJ Lenz
Journal / Conference
Journal of Clinical Oncology 30(supl 4; abstr 203); ASCO 2012 GI Cancers Symposium, poster presentation;
Year
2012
Research Committee(s)
Gastrointestinal
Study Number(s)
S0205

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (SWOG S0438) [PMID:22228638; PMC3481165; NIHMSID410808;]

Authors
K Margolin;J Moon;L Flaherty;C Lao;C Lao;M Othus;JA Sosman;J Kirkwood;V Sondak
Journal / Conference
Clinical Cancer Research 18(4):1129-1137;
Year
2012
Research Committee(s)
Melanoma
PMID
PMID22228638
PMC
PMC3481165
Study Number(s)
S0438

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

Authors
B Medeiros;M Othus;M Fang;F Appelbaum;E Estey
Journal / Conference
Cancer 118(9):2420-2423;
Year
2012
Research Committee(s)
Leukemia
PMID
PMID21928314
PMC
PMC3490403
Study Number(s)
S0106, S0112, SWOG-8600, SWOG-9031, SWOG-9034 (EST-3489) (CALGB-9120), SWOG-9126, SWOG-9333, SWOG-9500, S9617, S9910, S9918

Tumor-associated macrophages predict inferior outcomes in locally advanced and advanced stage classical Hodgkins lymphoma - a correlative study from the E2496 intergroup trial http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1568

Authors
KL Tan;DW Scott;F Hong;SJ Horning;RI Fisher;N Bartlett;L Shepherd;JM Connors;BS Kahl;LI Gordon;C Steidl;R Gascoyne
Journal / Conference
United States and Canadian Academy of Pathology, abst. #1568; poster presentation;
Year
2012
Research Committee(s)
Lymphoma
Study Number(s)
E2496

Patient reported cognitive impairments among women with breast cancer randomized to hormonal therapy alone versus chemotherapy followed by hormonal therapy: results from the TAILORx trial (PACCT-1)

Authors
L Wagner;R Gray;G Sledge;T Whelan;J Zujewski;DF Hayes;CE Geyer;EC Dees;J Sparano
Journal / Conference
International Cognition and Cancer Taskforce, 2012 meeting, poster;
Year
2012
Research Committee(s)
Breast

Effect of vitamin E and selenium on F2-isoprostanes, an oxidative stress biomarker, and lung function

Authors
KA Guertin;AR Kristal;KB Arnold;J Crowley;J Hartline;G Goodman;C Tangen;LM Minasian;SM Lippman;EA Klein;PA Cassano
Journal / Conference
Am J Respir Crit Care Med 185:2012:A6495; American Thoracic Society 2012 Intl Conf (May 18-23, 2012, San Francisco, CA), oral presentation;
Year
2012
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000C

Vitamin E and the risk of prostate cancer: updated results of the Selenium and Vitamin E Prevention Trial (SELECT)

Authors
EA Klein;IM Thompson;C Tangen;JJ Crowley;MS Lucia;PJ Goodman;L Minasian;LG Ford;H Parnes;JM Gaziano;DD Karp;M Lieber;PJ Walther;L Klotz;JK Parsons;JL Chin;AK Darke;SM Lippman;GE Goodman;FL Meyskens;LH Baker
Journal / Conference
Journal of Clinical Oncology (suppl 5; abstr 7); ASCO 2012 GU Sympos., oral presentation;
Year
2012
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

Authors
Y Qi;A Ziegler;S Hillman;M Redman;S Schild;D Gandara;A Adjei;S Mandrekar
Journal / Conference
Cancer 118(21):5358-5365;
Year
2012
Research Committee(s)
Lung
PMID
PMID22434489
PMC
PMC3481159
Study Number(s)
S0027, S0119, S0327, S0339, S0341, S0342, S0435

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with superficial bladder cancer with recurrence following 2 prior courses of BCG

Authors
E Skinner;B Goldman;W Sakr;D Petrylak;H Lenz;CT Lee;S Wilson;SP Lerner;C Tangen;IM Thompson
Journal / Conference
Journal of Urology 187, No. 4S, Supplement, e673, #1666; American Urological Association Annual Meeting, oral presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0353